NovaBiotics and the cystic fibrosis (CF) teams at Aberdeen Royal Infirmary are investigating the microbiological and mucolytic potential of Lynovex®, NovaBiotics’ drug candidate which is being developed as a novel treatment for cystic fibrosis. The collaboration with the CF clinical teams at Aberdeen Royal Infirmary allows NovaBiotics to access valuable clinical expertise and patient-derived samples so that Lynovex® can be tested (in CF sputum) under clinically relevant conditions and against the whole spectrum of very difficult to treat, drug-resistant bacteria from CF patients. NovaBiotics is delighted to be working with the CF teams and looks forward to a successful collaboration that will hopefully accelerate Lynovex® further towards the clinic as a much needed new therapy for CF.
Lynovex® is a Novel dual mucolytic-antibacterial agent it :
• Disrupts mucous (disulfide bond breaker)
• Disrupts & prevents bacterial biofilms
• Antibacterial against Gram-negative & Gram-positive respiratory bacteria
• Synergizes with inhaled antibiotics to potentiate their effects
Read the original story http://www.novabiotics.co.uk/News/Press.html#CFcollaboration which was published on 16th January 2013.